HR-HPV联合TCT在评估宫颈病变分类中的应用价值

目的分析高危型人乳头瘤病毒(HR-HPV)联合液基薄层细胞学检查(TCT)在评估宫颈病变分类中的应用价值。方法选取宫颈病变确诊治疗的患者500例,行TCT、HR-HPV检测,统计TCT、HR-HPV检测结果及病理宫颈病变情况,以病理活检结果为金标准,对HR-HPV、TCT单独检查及联合检查进行方法学评价。结果 500例病理诊断阳性227例、阴性273例;经HR-HPV联合TCT检测检出阳性302例,阴性198例,检测灵敏度为93.39%,特异度为67.03%,准确率为62.80%,阳性预测值为55.35%,阴性预测值为87.18%,灵敏度、特异性、准确率、阴性预测值较单项检测均提高。结论 HR-HPV联合TCT检测在宫颈病变评估中较单项检测诊断效能更高,有利于指导临床宫颈病变分类、宫颈癌筛查及疾病治疗等,进而能降低患者相关医疗费用和家庭经济负担,改善预后,具有良好的社会、经济效益。     

重组人干扰素治疗高危型HPV持续感染疗效观察

目的 探讨重组人干扰素治疗宫颈持续性高危型HPV(HR-HPV)感染的临床价值及机制.方法 将2011年1月至2013年1月在解放军150医院妇科门诊诊断为宫颈高危HPV持续感染且宫颈组织病理检查为宫颈上皮内瘤变Ⅰ级的113例患者分成实验组(重组干扰素肌注联合干扰素栓阴道后穹窿内放)68例和对照组(干扰素栓阴道后穹窿内放组)45例,连续治疗3个疗程.治疗后3个月、6个月后复查HPV-DNA.结果 实验组治疗后3个月患者HR-HPV转阴率显著高于对照组(x2=7.80,P＜0.01),实验组治疗后6个月患者HR-HPV转阴率显著高于对照组(x2=10.19,P＜0.01).两组患者无明显不良反应.结论 重组干扰素肌注联合阴道后穹窿放药能有效提高宫颈高危型HPV感染的转阴率,经济,方便,值得临床推广.     

高危型人乳头瘤病毒阴性/不典型鳞状细胞和低度鳞状上皮内病变患者的随访观察

目的分析高危型人乳头瘤病毒(high-risk human papillomavirus,HR-HPV)阴性的不典型鳞状细胞(atypical squamous cells undetermined significance,ASCUS)和低度鳞状上皮内病变(low squamous intraepithelial lesion,LSIL)患者的随访结果,探讨HR-HPV阴性的ASCUS和LSIL患者的合理处理方法。方法回顾性分析2010年1月1日至2012年12月31日期间,就诊于首都医科大学附属北京朝阳医院妇科门诊,HR-HPV阴性、宫颈液基细胞学为ASCUS和LSIL的356例患者的病理资料,对HR-HPV阴性的ASCUS和LSIL经阴道镜及宫颈活检排除高级别病变的306例患者定期进行HR-HPV随访。HR-HPV检测采用杂交检测法2代(hybird capture-Ⅱ,HC-Ⅱ)。结果 HR-HPV阴性/ASCUS和LSIL患者宫颈上皮内瘤变(cervical intraepithelial lesions,CIN)-Ⅲ及以上病变发病率分别为7.9%和9.1%。HR-HPV阳性/ASCUS和LSIL患者CIN-Ⅲ及以上病变发病率分别是22.9%和17.9%。HRHPV阳性的ASCUS和LSIL患者CIN-Ⅲ及以上病变发病率明显高于HR-HPV阴性患者,差异具有统计学意义(P=0.000)。HRHPV阳性对ASCUS及LSIL患者宫颈高级别病变的阴性预测值分别为87.13%和84.42%。HR-HPV阴性/ASCUS和LSIL患者CIN-Ⅱ及以上病变检出率是14.3%。不同年龄段的HR-HPV阴性/ASCUS和LSIL的患者,宫颈高级别病变患者的发生率不同,差异具有统计学意义(P<0.05)。30~39岁妇女宫颈高级别病变的发生率最高(18.2%)。结论 HR-HPV阴性的ASCUS和LSIL患者发生CIN-Ⅲ及以上病变分别是7.9%和9.1%,CIN-Ⅱ及以上病变达14.3%,30~39岁的HR-HPV阴性/ASCUS和LSIL患者宫颈高级别病变发生率达18%,建议对于HR-HPV阴性的ASCUS和LSIL患者应行阴道镜检查可疑病变部位活检。     

宫颈脱落细胞CA-IX的表达与高危型人乳头瘤病毒感染状态的相关性研究

目的探讨碳酸酐酶IX(carbonic anhydrase-IX,CA-IX)在宫颈脱落细胞中的表达情况及与高危型人乳头瘤病毒(high risk-human papilloma virus,HR-HPV)感染的关系,分析CA-IX预测宫颈病变自然转归方向的价值。方法运用免疫细胞化学技术观察CA-IX在不同宫颈病变宫颈脱落细胞中的表达,采用HC-Ⅱ测定HR-HPV DNA,定期随访,比较CA-IX表达与HR-HPV感染状态的相关性。结果 CA-IX的表达与HPV的感染存在相关性(χ2=81.8,P=0.000)。低级别〔宫颈炎、宫颈上皮内瘤变(cervical intraepithelial neoplasia,CIN-Ⅰ)〕和高级别(CIN-Ⅱ、CIN-Ⅲ及宫颈癌)宫颈病变,CA-IX的阳性表达率差异有统计学意义(χ2=4.5,P=0.032)。不同HPV感染状态下(持续性感染、一过性感染、无HPV感染),CA-IX表达的阳性率分别为60.6%、38.4%、15.6%,差异具有统计学意义(χ2=11.69,P=0.001)。结论 CA-IX的表达与HPV感染相关,在持续性HPV感染中,CA-IX的表达阳性率较一过性HPV感染、无HPV感染明显升高,提示CA-IX有可能是参与持续HPV感染致宫颈上皮内瘤变的分子标志之一。     

Synthetic genes: a tool for identifying human papillomavirus genotypes by hybridization and polymerase chain reaction-based assays

Obtaining positive polymerase chain reaction (PCR) controls for human papillomavirus (HPV) diagnostic tests has been difficult because of prevalence variation in different geographic regions of each high-risk viral type. Overlapping oligonucleotides were designed for HPV-18, HPV-31, HPV-45, and HPV-58 type-specific (TS) sequences. Synthetic HPV viral genes were constructed by 2-step assembly PCR for accurately diagnosing TS HPV infection.     

Consistency evaluation of Liferiver,Yaneng, Darui,and the Cobas 4800 test for high-risk human papillomavirus screening

BackgroundIn recent years, several high‐risk human papillomavirus (HR‐HPV) tests have been developed. The assay capabilities need to be systematically reviewed. Here, we compared the clinical sample performance of three novel HR‐HPV assays (Liferiver, Yaneng, and Darui) based on different platforms with the widely adopted cobas4800 test.MethodsA total of 346 cervical swabs from women who were screened for cervical cancer were analyzed for the presence of 14 HR‐HPV genotypes. The distinction between the four assays was investigated by the genotyping and direct sequencing.ResultsThe positive rates of the four assays ranged from 61.56% to 64.16%. The overall concordance was 88.15%. The Yaneng assays displayed the best sensitivity (100%) and specificity (98.43%). The sensitivity (98.17%) and specificity (98.43%) of the Darui assay were superior to those of the cobas4800 test (97.72% and 93.70%, respectively). The Liferiver assay displayed comparable sensitivity with the cobas4800 test (95.89% and 97.72%, respectively). The specificity of the cobas4800 was lower than that of the Liferiver assay (93.70% vs. 97.64%).ConclusionsThe three novel HR‐HPV assays displayed good agreement with the cobas4800 test. The analytical performance of all four fulfilled the requirements of sensitivity and specificity for HR‐HPV detection.     

TCT、HR-HPV检测及宫颈活检在宫颈早期病变中的诊断价值

目的:评价膜式液基薄层细胞学技术(thin prep liquid-based cytology test,TCT)、高危型人乳头状瘤病毒(high-risk human papillomavirus,HR-HPV)检测及阴道镜下宫颈活检对宫颈早期病变的诊断价值。方法:640例TCT检查异常的患者中,320例应用杂交捕获技术(HC-Ⅱ)检测HR-HPV,372例进行阴道镜检查并取宫颈组织活检,同时行HR-HPV检测及阴道镜检查并取宫颈组织活检者272例。以病理学为标准,比较三种方法对宫颈早期病变的诊断价值。结果:①HR-HPV检测能降低TCT假阴性,且随宫颈细胞学检查级别增加,HR-HPV阳性率增加(P<0.05)。②宫颈活检细胞阳性检出率明显高于TCT阳性检出率(P<0.01);HR-HPV阳性组CIN发病率明显高于阴性组(P<0.01);HR-HPV阳性组宫颈病变程度明显高于阴性组(P<0.05);HPV感染病理诊断率明显高于阴性组(P<0.01)。③阴道镜下宫颈活检可降低HR-HPV检测的漏诊率。④随宫颈细胞学检查级别增加,HPV感染发生率增加,CIN发生率增加,宫颈活检病理诊断HPV感染率增加(P<0.01);TCT、HR-HPV检测联合阴道镜下宫颈活检阳性率可达100%。结论:TCT、HR-HPV检测及阴道镜下宫颈活检是子宫颈病变早期诊断不可或缺的辅助手段;三者各有优缺点,不能相互替代,三者结合可提高宫颈早期病变的检出率。     

重组人干扰素a-2b阴道泡腾胶囊治疗生殖道HR-HPV感染96例临床分析

目的对应用α-2b阴道泡腾胶囊对生殖道HR-HPV感染的患者进行治疗的临床效果进行研究分析。方法抽取192例生殖道HR-HPV感染患者病例,将其分为对照组和治疗组,平均每组96例。对照组患者采用保妇康进行治疗;治疗组患者采用保妇康与α-2b阴道泡腾胶囊联合进行治疗。结果治疗组患者的病情控制效果明显优于对照组;出现不良反应的人数明显少于对照组;治疗后症状再次复发率明显低于对照组。结论应用α-2b阴道泡腾胶囊对生殖道HR-HPV感染的患者进行治疗的临床效果非常明显。     

High Grade Cervical Intraepithelial Neoplasia and Viral Load of High-Risk Human Papillomavirus: Significant Correlations in Patients of 22 Years Old or Younger

High-risk human papillomavirus (HR-HPV) is recognized as the primary cause for the development of cervical cancers and their precursor lesions. We investigated whether high-grade cervical dysplasia correlates with high viral load of HR-HPV in an age-dependent manner. Cases were retrospectively selected to include patients with a prior cytological diagnosis of ASCUS or higher grade squamous intraepithelial lesions, and a positive Digene Hybrid Capture II (HC-II) HR-HPV testing within 2 months before or after cervical biopsy. The quantitative viral load data was classified as negative, low, moderate and high according to the manufacturer’s instruction. Cases were then stratified into 4 age groups: ≤22 years, 23-30 years, 31-40 years and >40 years. Chi-Square analysis and logistic regression were performed where appropriate. A total of 995 patients were identified. Age categories were significantly associated with HPV loads (p=0.046). Moderate to high viral loads of HPV were significantly related to the histological grade of dysplasia (p=0.029). Logistic regression analysis further confirmed the association of HPV with histological grades, even after adjusting for age factor. In particular, high-grade dysplasia (p=0.011) but not low grade dysplasia (p=0.140) was significantly associated with moderate to high HPV loads. Patients of 22 years old or younger were the only group found significantly correlated with high viral loads of HPV (p=0.015). In conclusion, high-grade squamous intraepithelial lesions and patients’ age of 22 years old or younger are significantly associated with a moderate to high viral load of HR-HPV.     

深圳公明镇高危型HPV感染现状及年龄分布

目的调查深圳公明镇妇女高危型HPV感染现状及年龄分布,为HPV疫苗的使用提供理论依据。方法对本院妇科2010年1月至2012年12月的10800例就诊妇女作21种HPV基因型别检测,结合患者年龄信息用卡方检验对检测结果作统计分析。结果 HPV总感染率为38.5%（4158例）;高危型HPV的感染率达到28.4%（3067例）,单一高危型HPV感染占85.2%（2613例）,以16型（932例）为主;经统计分析高危型HPV感染率在不同年龄段妇女间差异有统计学意义（P〈0.05）。结论深圳公明镇女性HPV感染情况与年龄分布与国内其他地区有一定差异,提示应用HPV疫苗时应考虑分型及年龄因素。